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Intracoronary Delivery of Hematopoietic Bone Marrow Stem Cells and Luminal Loss of the
Infarct-Related Artery in Patients With Recent Myocardial Infarction
To the Editor: Angiogenesis and atherogenesis share a number of
pathways suggesting that interrelated tradeoffs might be inherent
to therapies designed to enhance collateral formation and cardiac
repair (1). This “Janus-like” effect on atherosclerosis progression
was observed in several experimental models exposed to therapy
with bone marrow stem cells (BMSCs) (1–4). A recent clinical
study reported high rates of in-stent restenosis after BMSC
mobilization (5). In our study (6), CD133 enriched BMSC
exerted beneficial effects on cardiac recovery in patients with
reperfused myocardial infarction, but the restenosis rates were also
higher as expected after intracoronary BMSC therapy (7–11).
Hence, we investigated the effects of intracoronary CD133
enriched BMSC on in-stent neointimal proliferation and distal
atherosclerosis progression in patients with recent myocardial
infarction treated with angioplasty using bare-metal stents.
Thirty-eight patients with acute myocardial infarction due to
occlusion of the proximal left anterior descending coronary artery
(LAD) were studied. The cell group consisted of 21 patients
receiving intracoronary injection of CD133 enriched BMSC and
follow-up catheterization with quantitative coronary angiography
(QCA) and coronary functional assessment with the pressure-
derived fractional flow reserve (FFR) (12,13). The control group
consisted of 17 patients matched for ejection fraction, infarction
size, and location with control catheterization between 4 and 8
months after the infarction. Segmental QCA analysis was per-
formed for the stented segment and non-stented portion of the
mid LAD and distal LAD. Data are shown as mean  SEM.
Paired t test and unpaired t test were used as appropriate.
There were no differences in clinical and demographic charac-
teristics between groups (not shown). Baseline angiographic and
functional characteristics are shown in Table 1. At follow-up, no
significant changes were noted in luminal diameters of the con-
tralateral artery (CLA) of either group (from 2.66  0.09 mm to
2.65  0.10 mm in the cell group, and from 2.71  0.14 mm to
2.78  0.17 mm in the control group, both p  NS). In contrast,
higher loss index of the stented segment in the cell group (0.42 
0.07 vs. 0.22  0.06, p  0.05) was paralleled by a greater
leftward shift in the cumulative distribution of the minimal
luminal diameter (MLD) as compared with the control group (Fig.
1A). In non-stented segments, cumulative luminal loss of the
reference diameter (RD) and MLD at the mid and distal segment
of the infarct-related artery (IRA) were higher in the cell group
Table 1. Baseline Angiographic Characteristics After Stented
Angioplasty Before Cell Injection
CD 133
(n  21)
Control
Subjects
(n  17) p Value
IRA—after stenting
RD stent (mm) 3.24  0.08 3.32  0.09 NS
MLD stent (mm) 2.84  0.10 2.93  0.12 NS
Nominal stent
diameter (mm)
3.25  0.07 3.31  0.08 NS
Nominal stent
length (mm)
21.8  1.5 25.5  2.6 NS
Distal IRA
RD mid segment (mm) 2.69  0.13 2.81  0.11 NS
MLD mid segment (mm) 2.21  0.11 2.31  0.15 NS
RD distal segment (mm) 2.03  0.08 2.38  0.11 0.05
MLD distal
segment (mm)
1.70  0.07 2.06  0.11 0.05
FFR IRA 0.86  0.02 0.83  0.02 NS
CLA
RD (mm) 2.66  0.09 2.71  0.14 NS
MLD (mm) 2.22  0.11 2.24  0.16 NS
FFR CLA 0.89  0.02 0.94  0.02 NS
CLA  contralateral artery; DS  diameter stenosis; FFR  fractional flow reserve;
IRA  infarct-related artery; MLD  minimal luminal diameter; RD  reference
diameter.
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Figure 1. (A) Cumulative distribution of the minimal luminal diameter (MLD) within the stented segment in cells patients (line) and control subjects (line
with full dots) after stented angioplasty and at follow-up. (B) Luminal loss (LL) of the reference diameter (RD) and MLD of distal non-stented segments
of the infarct related artery (IRA) in all patients. (C) Luminal loss of the RD and MLD of distal non-stented segments of the IRA in patients without
in-stent restenosis (ISR).
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(Fig. 1B) or in the subgroup of patients without significant in-stent
restenosis, as compared with relevant control subjects (Fig. 1C).
Significant distal de novo stenosis (50% stenosis) was seen in two
patients in the cell group and none in control subjects. In a subset
of the cell group patients undergoing serial intravascular ultrasound
study (n  5), plaque burden significantly increased in the IRA
(from 45.9  4.3% to 56.3  3.9%, p  0.05) but remained
unchanged in the CLA of the same patients (from 40.5  1.3% to
40.3  1.2%, p  NS).
Luminal changes by QCA were associated with a significant
decrease in FFR of the IRA in the cell group, with no change in
the control group (0.21  0.05 vs. 0.01  0.04, p  0.05). In
patients without in-stent restenosis, the cell group showed a higher
decrease in FFR as compared with relevant control subjects (0.13
0.05 vs. 0.06  0.03, p  0.05). The cell group patients receiving
9  106 CD133 cells showed larger luminal loss in the mid
non-stented segment of the IRA as compared with patients
receiving a lower number of cells (0.87  0.19 mm vs. 0.25 
0.21 mm, p  0.05). The cell group patients with in-stent restenosis
or a de novo stenosis showed lower systemic interleukin-10 levels
(1.95  0.96 ng/ml vs. 5.01  1.82 ng/ml, p  0.07) and higher
vascular endothelial growth factor (VEGF)-A levels (215.5 42.9
pg/ml vs. 86.3  29.0 pg/ml, p  0.05) as compared with the cell
group patients without new lesion or restenosis. No differences in
plasma interleukin-6, monocyte chemoattractant protein-1, and
basic fibroblast growth factor levels between groups were observed
(not shown).
Present data indicate that intracoronary injection of enriched
BMSC is associated with greater in-stent proliferation and larger
luminal loss in non-stented IRA segments that result in a signif-
icant decrease in pressure-derived FFR. These changes are consis-
tent with decreased epicardial conductance of the IRA, owing to
diffuse luminal loss and increased plaque burden. Our study
suggests several mechanisms for the “Janus-like” effect. First, the
total number of CD34 or CD133 cells in the cell suspension
was higher than in previous studies (5–11), and patients with a
higher number of injected CD133 cells showed a larger luminal
loss of distal non-stented segments. Hence, dose-dependent in-
crease in local concentrations of pro-angiogenic molecules might
have exacerbated pro-atherogenic effects. Second, cell-treated pa-
tients with in-stent restenosis or a de novo stenosis showed lower
levels of interleukin-10 and higher levels of serum VEGF-A,
suggesting disequilibrium between pro-atherogenic and anti-
atherogenic factors as a predisposing factor. Nevertheless, local
concentration of inflammatory cytokines or biological activity of
CD133 could provide further insights into these hypotheses. As
an alternative mechanism, in-stent proliferation might be related
to repetitive balloon occlusion at the time of the cell injection,
albeit at low inflation pressure, by impairing ongoing re-
endothelialization. Note that earlier studies (6,14) demonstrated
immunological safety of immunomagnetic isolation with absence
of human anti-mouse antibodies after stem cell enrichment in
bone marrow transplant patients, which argues against immuno-
logical response as the underlying mechanism.
In conclusion, our findings of reduced luminal diameters and
epicardial conductance of the IRA, as assessed from the pressure-
derived FFR, seem to be consistent with a higher risk for
atherosclerosis progression after intracoronary administration of
enriched BMSC. Yet, these data were obtained from retrospective
analysis; they lack randomized controls and systematic use of
intravascular ultrasound imaging to track changes in the vascular
wall. Future and ongoing randomized studies using intracoronary
injection of enriched and unfractionated BMSC should define the
risk and mechanisms of potential “Janus-like” effects on the
epicardial coronary circulation.
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Glucose-Insulin-Potassium Infusion in Patients With Acute Myocardial Infarction Without
Signs of Heart Failure: The Glucose-Insulin-Potassium Study (GIPS)-II
To the Editor: Metabolic support through glucose-insulin-
potassium (GIK), in adjunct to reperfusion therapy, might improve
outcome in patients with ST-segment elevation myocardial infarc-
tion (STEMI) (1). The Glucose-Insulin-Potassium Study
(GIPS)-I showed clinical benefit of GIK in STEMI patients
without signs of heart failure (2). To verify these findings we
performed a second study investigating GIK in patients without
signs of heart failure treated with reperfusion therapy.
It concerns a randomized, open label study (3); STEMI
patients without signs of heart failure on admission were
randomized to traditional care or additional GIK infusion.
Glucose-potassium (20% glucose with 80 mmol potassium/l)
was infused at 2 ml/kg body weight per hour for 12 h through
a peripheral line. Short-acting insulin was started according to
admission glucose and adjusted on the basis of hourly measured
glucose.
Primary end point was 30-day mortality. Enzymatic infarct size
was estimated by the highest value of creatine kinase (peak CK).
Multivariate analyses (including all univariate predictors and GIK
intervention) were performed to identify independent predictors of
30-day mortality (Cox regression) and high enzymatic infarct size
(logistic regression). A sample size of 1,044 patients was planned,
on the basis of the mortality reduction in non-heart-failure
patients as reported in GIPS-I (1.2% vs. 4.2%) (2).
Patient inclusion started August 2003. After planned interim
analysis, the study was terminated in December 2004, because a
significant difference was unlikely to be reached on further inclusion.
A total of 889 patients were included (Table 1). Anterior
infarct location was more common in the GIK group, and
previous percutaneous coronary intervention (PCI) more com-
mon in the control group. All other general characteristics were
comparable between the two treatment groups. Reperfusion ther-
apy consisted of primary PCI (n  778, 88%) or thrombolysis (n 
65). Mean starting insulin dose in the GIK group was 9.6 7.5 U/h.
During 30 days’ follow-up, 13 patients (2.9%) died in the GIK group
and 8 patients (1.8%) died in the control group (odds ratio [OR] 1.6;
95% confidence interval [CI]: 0.7 to 4.0, p  0.27) (Fig. 1).
Multivariate analyses showed that failed reperfusion, anterior infarct
location, and higher admission glucose but not GIK infusion (OR 1.5;
95% CI: 0.6 to 3.9) were independent predictors of 30-day mortality.
Mean peak CK was 2,008  1,930 U/l in patients treated with
GIK compared with 1,932  1,847 U/l in control subjects (p 
0.57). The prevalence of a high enzymatic infarct size (CK levels
in the upper tertile [2,149 U/l]) was comparable between
patients treated with GIK and control subjects (34% vs. 32%, p 
0.57). Multivariate analysis did not change these findings.
We could not confirm the previously observed benefit of GIK
in STEMI patients without signs of heart failure. Because the
sample size of the GIPS-II trial was based on the results of the
GIPS-I trial, it was not powered to demonstrate smaller
benefits of GIK; however, not even a trend toward a therapeutic
benefit was observed in our trial. Combined with the results of
other trials, it can be concluded that, in the used regimen, GIK
in adjunct to reperfusion therapy in STEMI patients does not
lower mortality.
Previous reports on the effect of GIK in STEMI have been
contradictory. The meta-analysis of Fath-Ordoubadi and Beatt
(4) showed a benefit of GIK infusion; however, studies included
in this meta-analysis were of older date, and none of the
Table 1. Baseline Characteristics of the Patient Groups
GIK Group
(n  444)
Control Group
(n  445) p Value
Age (yrs) 61.8  12.4 61.2  12.3 0.51
Age 60 yrs 242 (55%) 243 (55%) 0.98
Men 326 (73%) 329 (74%) 0.86
Previous MI 37 (8%) 54 (12%) 0.06
Previous PCI 27 (6%) 48 (11%) 0.01
Previous CABG 6 (1%) 11 (3%) 0.22
Diabetes 41 (9%) 46 (10%) 0.57
Diabetes using insulin 12 (3%) 10 (2%) 0.66
Hypertension 146 (33%) 125 (28%) 0.13
Positive family history 190 (46%) 201 (48%) 0.57
Systolic blood pressure
(mm Hg)
135.3  25.7 132.5  24.0 0.11
Diastolic blood pressure
(mm Hg)
80.5  15.9 79.0  15.0 0.18
Anterior infarction 210 (48%) 172 (39%) 0.01
Ischemic time 229  143 220  112 0.31
Reperfusion therapy 418 (94%) 426 (96%) 0.28
Primary PCI 391 (88%) 387 (87%)
Rescue PCI 23 (6%) 26 (6%)
Thrombolysis 4 (1%) 12 (3%)
Reperfusion successful 395 (95%) 404 (95%) 0.83
Mean glucose on
admission (mmol/l)
8.5  2.8 8.3  2.5 0.51
Discharge medication in
the patient groups
Aspirin 422 (95%) 415 (93%) 0.26
Coumadin 17 (4%) 19 (4%) 0.74
Clopidrogel 396 (89%) 391 (88%) 0.54
Beta-blocker 402 (91%) 384 (86%) 0.048
Statin 392 (88%) 387 (87%) 0.55
ACE inhibitor 261 (59%) 251 (56%) 0.47
Oral anti-glycemic agent 25 (6%) 28 (6%) 0.68
Insulin 12 (3%) 15 (3%) 0.56
ACE  angiotensin-converting enzyme; CABG  coronary artery bypass grafting;
GIK  glucose insulin potassium; MI  myocardial infarction; PCI  percutaneous
coronary intervention.
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